<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147068</url>
  </required_header>
  <id_info>
    <org_study_id>PSC22 GLA-SE</org_study_id>
    <nct_id>NCT01147068</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults</brief_title>
  <official_title>A Two-Part Placebo-Controlled Evaluation of the Safety and Immunogenicity of an A/Indonesia/5/05 Recombinant Hemagglutinin Influenza H5N1 Vaccine With and Without Glucopyranosyl Lipid A (GLA-SE) in Healthy Adults 18-49</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protein Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protein Sciences Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and immunogenicity of a recombinant
      hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at
      4 dose levels in adjuvanted (GLA-SE) rHA formulations and 2 dose levels in unadjuvanted rHA
      formulations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All currently licensed influenza vaccines in the United States are produced in embryonated
      hen's eggs. There are several well-recognized disadvantages to the use of eggs as the
      substrate for influenza vaccine. Eggs require specialized manufacturing facilities and could
      be difficult to scale up rapidly in response to an emerging need such as a pandemic. It is
      usually necessary to adapt candidate vaccine viruses for high-yield growth in eggs, a process
      that can be time consuming, is not always successful, and can select receptor variants that
      may have suboptimal immunogenicity. In addition, agricultural diseases that affect chicken
      flocks, and that might be an important issue in a pandemic due to an avian influenza virus
      strain, could easily disrupt the supply of eggs for vaccine manufacturing. Therefore,
      development of alternative substrates for influenza vaccine production has been identified as
      a high-priority objective.

      One potential alternative method for production of influenza vaccine is expression of the
      influenza virus hemagglutinin (HA) using recombinant DNA techniques. This alternative avoids
      dependence on eggs and is very efficient because of the high levels of protein expression
      under the control of the baculovirus polyhedrin promoter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age.</measure>
    <time_frame>42 Days</time_frame>
    <description>Immunogenicity was assessed by measuring the percentage of subjects in each group exhibiting seroconversion on Day 42. The treatment groups that received adjuvanted rHA were evaluated against non-adjuvanted rHA and placebo groups for whether they demonstrated seroconversion rates and 95% confidence intervals that met regulatory criterion for licensure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation and Comparison of Immunogenicity From Geometric Mean Titers of PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age.</measure>
    <time_frame>Day 0, and Day 42</time_frame>
    <description>Immunogenicity was assessed by measuring the proportion of subjects that exhibited a geometric mean titer change from Day 0 to Day 42. The geometric mean titers from the PanBlok groups (with and without adjuvant)and placebo group were then compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serologic Response Rates at Day 21 Using PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age</measure>
    <time_frame>21 Days</time_frame>
    <description>Immunogenicity was assessed by measuring the seroconversion rates of subjects from Day 0 to Day 21 to determine and evaluate the immune response following a single dose of study vaccine. The results were compared using PanBlok with and without adjuvant and placebo in healthy adults</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>PanBlok 135µg No Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PanBlok 45µg No Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PanBlok 45µg and GLA 1.0µg, SE 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PanBlok 15µg and GLA 1.0µg, SE 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PanBlok 7.5µg and GLA 1.0µg, SE 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PanBlok 3.8µg and GLA 1.0µg, SE 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>0.5mL Intramuscular Injection</intervention_name>
    <description>0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
    <arm_group_label>PanBlok 135µg No Adjuvant</arm_group_label>
    <arm_group_label>PanBlok 45µg No Adjuvant</arm_group_label>
    <arm_group_label>PanBlok 45µg and GLA 1.0µg, SE 2%</arm_group_label>
    <arm_group_label>PanBlok 15µg and GLA 1.0µg, SE 2%</arm_group_label>
    <arm_group_label>PanBlok 7.5µg and GLA 1.0µg, SE 2%</arm_group_label>
    <arm_group_label>PanBlok 3.8µg and GLA 1.0µg, SE 2%</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>rHA</other_name>
    <other_name>recombinant hemagglutinin</other_name>
    <other_name>PanBlok</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18-49 years.

          -  Give written informed consent to participate.

          -  Healthy, as determined by medical history, physical examination, vital signs, and
             clinical safety laboratory evaluation

          -  Females should fulfill one of the following criteria:

               -  At least one year post-menopausal;

               -  Surgically sterile;

               -  Will use oral, implantable, transdermal or injectable contraceptives for 30 days
                  prior to first vaccination and until 28 days after the booster vaccination; or

               -  Willing to use another reliable form of contraception approved by the
                  Investigator (e.g., intrauterine device (IUD), female condom, diaphragm with
                  spermicide, cervical cap, use of condom by the sexual partner or a sterile sexual
                  partner) for 30 days prior to first vaccination and until 28 days after the
                  booster vaccination.

          -  Women of childbearing potential must have a negative urine pregnancy test within 24
             hours preceding receipt of first and booster vaccinations

          -  Comprehension of the study requirements, expressed availability for the required study
             period, and ability to attend scheduled visits.

        Exclusion Criteria:

          -  Persons under 18 years old or 50 years or older

          -  Persons with chronic illnesses such as cancer, diabetes, liver or kidney disease

          -  Persons taking medications or treatments that may adversely affect the immune system

          -  Persons with known allergy to eggs or other vaccine or adjuvant components

          -  Person currently pregnant, nursing mothers or planning a pregnancy within one month of
             vaccination

          -  Persons who have had a prior serious reaction to any influenza vaccine

          -  Persons with a known history of Guillain-Barré Syndrome

          -  Persons with a history of anaphylactic-type reaction to injected vaccines

          -  Persons with a history of drug or chemical abuse in the year preceding the study

          -  Persons who previously received an H5N1 influenza vaccine or who plan to receive an
             H5N1 influenza vaccine while participating in the study

          -  Persons who received a seasonal influenza vaccine six months prior to enrollment (may
             delay enrollment)

          -  Persons who received any other vaccine within one week prior to enrollment (may delay
             enrollment)

          -  Persons who have had a respiratory illness or illness with fever within three days of
             study enrollment (may delay enrollment)

          -  Persons currently participating in another research study involving any study
             medications (investigational drugs or vaccines).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Treanor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://proteinsciences.com</url>
  </link>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <results_first_submitted>October 24, 2012</results_first_submitted>
  <results_first_submitted_qc>October 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2012</results_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Protein Sciences Corporation</investigator_affiliation>
    <investigator_full_name>Manon M.J. Cox</investigator_full_name>
    <investigator_title>CEO</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adults 18-49 years of age were screened in participating outpatient clinics for eligibility within 30 days of randomization during the 2010 influenza season.</recruitment_details>
      <pre_assignment_details>Subjects whose laboratory values were exclusionary were not randomized. Women of child-bearing potential were required to have a negative pregnancy test.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="P2">
          <title>PanBlok 135µg No Adjuvant</title>
          <description>135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="P3">
          <title>PanBlok 45µg No Adjuvant</title>
          <description>45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="P4">
          <title>PanBlok 45µg and GLA 1.0µg, SE 2%</title>
          <description>45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="P5">
          <title>PanBlok 15µg and GLA 1.0µg, SE 2%</title>
          <description>15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="P6">
          <title>PanBlok 7.5µg and GLA 1.0µg, SE 2%</title>
          <description>7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="P7">
          <title>PanBlok 3.8µg and GLA 1.0µg, SE 2%</title>
          <description>3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Subjects That Received 1st Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="53"/>
                <participants group_id="P7" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="53"/>
                <participants group_id="P7" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Subjects That Received 2nd Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="53"/>
                <participants group_id="P7" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="55"/>
                <participants group_id="P6" count="51"/>
                <participants group_id="P7" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not complete the study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Subjects That Completed Safety Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60">Participants were eligible for follow-up regardless of number of doses received.</participants>
                <participants group_id="P2" count="57">One subject was ineligible, one subject did not complete the study, and the other data is unknown.</participants>
                <participants group_id="P3" count="55">Data on three subjects is unknown.</participants>
                <participants group_id="P4" count="56"/>
                <participants group_id="P5" count="56">Data for one subject is unknown.</participants>
                <participants group_id="P6" count="53">One subject was lost to follow up and one subject did not complete the study.</participants>
                <participants group_id="P7" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="B2">
          <title>PanBlok 135µg No Adjuvant</title>
          <description>135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="B3">
          <title>PanBlok 45µg No Adjuvant</title>
          <description>45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="B4">
          <title>PanBlok 45µg and GLA 1.0µg, SE 2%</title>
          <description>45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="B5">
          <title>PanBlok 15µg and GLA 1.0µg, SE 2%</title>
          <description>15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="B6">
          <title>PanBlok 7.5µg and GLA 1.0µg, SE 2%</title>
          <description>7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="B7">
          <title>PanBlok 3.8µg and GLA 1.0µg, SE 2%</title>
          <description>3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="56"/>
            <count group_id="B5" value="56"/>
            <count group_id="B6" value="53"/>
            <count group_id="B7" value="55"/>
            <count group_id="B8" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The median was measured based on the total population of each arm.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.0" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B2" value="30.0" lower_limit="18" upper_limit="48"/>
                    <measurement group_id="B3" value="32.0" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B4" value="31.0" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B5" value="33.5" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B6" value="27.0" lower_limit="19" upper_limit="48"/>
                    <measurement group_id="B7" value="33.0" lower_limit="19" upper_limit="49"/>
                    <measurement group_id="B8" value="32.2" lower_limit="18" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="34"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age.</title>
        <description>Immunogenicity was assessed by measuring the percentage of subjects in each group exhibiting seroconversion on Day 42. The treatment groups that received adjuvanted rHA were evaluated against non-adjuvanted rHA and placebo groups for whether they demonstrated seroconversion rates and 95% confidence intervals that met regulatory criterion for licensure.</description>
        <time_frame>42 Days</time_frame>
        <population>All randomized subjects who received study vaccine and had Day 0 and Day 42 efficacy data. The analysis results are generated by Southern Research Institute on the intention to treat efficacy population using whole virus.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O2">
            <title>PanBlok 135µg No Adjuvant</title>
            <description>135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O3">
            <title>PanBlok 45µg No Adjuvant</title>
            <description>45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O4">
            <title>PanBlok 45µg and GLA 1.0µg, SE 2%</title>
            <description>45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O5">
            <title>PanBlok 15µg and GLA 1.0µg, SE 2%</title>
            <description>15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O6">
            <title>PanBlok 7.5µg and GLA 1.0µg, SE 2%</title>
            <description>7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O7">
            <title>PanBlok 3.8µg and GLA 1.0µg, SE 2%</title>
            <description>3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age.</title>
          <description>Immunogenicity was assessed by measuring the percentage of subjects in each group exhibiting seroconversion on Day 42. The treatment groups that received adjuvanted rHA were evaluated against non-adjuvanted rHA and placebo groups for whether they demonstrated seroconversion rates and 95% confidence intervals that met regulatory criterion for licensure.</description>
          <population>All randomized subjects who received study vaccine and had Day 0 and Day 42 efficacy data. The analysis results are generated by Southern Research Institute on the intention to treat efficacy population using whole virus.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="32" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="O3" value="15" lower_limit="8" upper_limit="27"/>
                    <measurement group_id="O4" value="82" lower_limit="69" upper_limit="90"/>
                    <measurement group_id="O5" value="75" lower_limit="62" upper_limit="84"/>
                    <measurement group_id="O6" value="66" lower_limit="53" upper_limit="77"/>
                    <measurement group_id="O7" value="72" lower_limit="58" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation and Comparison of Immunogenicity From Geometric Mean Titers of PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age.</title>
        <description>Immunogenicity was assessed by measuring the proportion of subjects that exhibited a geometric mean titer change from Day 0 to Day 42. The geometric mean titers from the PanBlok groups (with and without adjuvant)and placebo group were then compared.</description>
        <time_frame>Day 0, and Day 42</time_frame>
        <population>All randomized subjects who received study vaccine and had Day 0 and Day 42 geometric mean titers. Analysis of results were generated by Southern Research Institute on the overall population using whole virus.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O2">
            <title>PanBlok 135µg No Adjuvant</title>
            <description>135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O3">
            <title>PanBlok 45µg No Adjuvant</title>
            <description>45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O4">
            <title>PanBlok 45µg and GLA 1.0µg, SE 2%</title>
            <description>45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O5">
            <title>PanBlok 15µg and GLA 1.0µg, SE 2%</title>
            <description>15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O6">
            <title>PanBlok 7.5µg and GLA 1.0µg, SE 2%</title>
            <description>7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O7">
            <title>PanBlok 3.8µg and GLA 1.0µg, SE 2%</title>
            <description>3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation and Comparison of Immunogenicity From Geometric Mean Titers of PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age.</title>
          <description>Immunogenicity was assessed by measuring the proportion of subjects that exhibited a geometric mean titer change from Day 0 to Day 42. The geometric mean titers from the PanBlok groups (with and without adjuvant)and placebo group were then compared.</description>
          <population>All randomized subjects who received study vaccine and had Day 0 and Day 42 geometric mean titers. Analysis of results were generated by Southern Research Institute on the overall population using whole virus.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="53"/>
                <count group_id="O7" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Titer was below limit of detection</measurement>
                    <measurement group_id="O2" value="NA">Titer was below limit of detection</measurement>
                    <measurement group_id="O3" value="NA">Titer was below limit of detection</measurement>
                    <measurement group_id="O4" value="NA">Titer was below limit of detection</measurement>
                    <measurement group_id="O5" value="NA">Titer was below limit of detection</measurement>
                    <measurement group_id="O6" value="NA">Titer was below limit of detection</measurement>
                    <measurement group_id="O7" value="NA">Titer was below limit of detection</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Titer was below limit of detection</measurement>
                    <measurement group_id="O2" value="16.7" lower_limit="12" upper_limit="24"/>
                    <measurement group_id="O3" value="10.7" lower_limit="8" upper_limit="14"/>
                    <measurement group_id="O4" value="128.4" lower_limit="93" upper_limit="177"/>
                    <measurement group_id="O5" value="94.5" lower_limit="63" upper_limit="142"/>
                    <measurement group_id="O6" value="68.7" lower_limit="45" upper_limit="104"/>
                    <measurement group_id="O7" value="71.7" lower_limit="47" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serologic Response Rates at Day 21 Using PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age</title>
        <description>Immunogenicity was assessed by measuring the seroconversion rates of subjects from Day 0 to Day 21 to determine and evaluate the immune response following a single dose of study vaccine. The results were compared using PanBlok with and without adjuvant and placebo in healthy adults</description>
        <time_frame>21 Days</time_frame>
        <population>All randomized subjects with Day 0 and Day 21 data analyzed by Cincinnati Children's Hospital Medical Center using the intent to treat population and CBER antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O2">
            <title>PanBlok 135µg No Adjuvant</title>
            <description>135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O3">
            <title>PanBlok 45µg No Adjuvant</title>
            <description>45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O4">
            <title>PanBlok 45µg and GLA 1.0µg, SE 2%</title>
            <description>45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O5">
            <title>PanBlok 15µg and GLA 1.0µg, SE 2%</title>
            <description>15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O6">
            <title>PanBlok 7.5µg and GLA 1.0µg, SE 2%</title>
            <description>7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
          <group group_id="O7">
            <title>PanBlok 3.8µg and GLA 1.0µg, SE 2%</title>
            <description>3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
          </group>
        </group_list>
        <measure>
          <title>Serologic Response Rates at Day 21 Using PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age</title>
          <description>Immunogenicity was assessed by measuring the seroconversion rates of subjects from Day 0 to Day 21 to determine and evaluate the immune response following a single dose of study vaccine. The results were compared using PanBlok with and without adjuvant and placebo in healthy adults</description>
          <population>All randomized subjects with Day 0 and Day 21 data analyzed by Cincinnati Children's Hospital Medical Center using the intent to treat population and CBER antigen.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="52"/>
                <count group_id="O7" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.4" upper_limit="11.5"/>
                    <measurement group_id="O2" value="4" lower_limit="0.4" upper_limit="12.3"/>
                    <measurement group_id="O3" value="4" lower_limit="0.5" upper_limit="12.7"/>
                    <measurement group_id="O4" value="11" lower_limit="4" upper_limit="21.9"/>
                    <measurement group_id="O5" value="7" lower_limit="2" upper_limit="17.3"/>
                    <measurement group_id="O6" value="8" lower_limit="2.1" upper_limit="18.5"/>
                    <measurement group_id="O7" value="2" lower_limit="0" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events - 28 days following immunization; Serious adverse events, adverse events of special interest, and new onset of chronic illnesses for duration of 12-month follow-up after immunization.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="E2">
          <title>PanBlok 135µg No Adjuvant</title>
          <description>135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="E3">
          <title>PanBlok 45µg No Adjuvant</title>
          <description>45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="E4">
          <title>PanBlok 45µg and GLA 1.0µg, SE 2%</title>
          <description>45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="E5">
          <title>PanBlok 15µg and GLA 1.0µg, SE 2%</title>
          <description>15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="E6">
          <title>PanBlok 7.5µg and GLA 1.0µg, SE 2%</title>
          <description>7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
        <group group_id="E7">
          <title>PanBlok 3.8µg and GLA 1.0µg, SE 2%</title>
          <description>3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
0.5mL Intramuscular Injection : 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Abdominopelvic Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of Right Ankle Instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Post-operative Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Unspecified Protein Calorie Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Intrauterine Fetal Demise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Left Upper Lobe Lung Nodule with Organizing Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Fractured/Cracked Vertebrae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pinched nerve between C3-6</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="38" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Cholesterol Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Joint Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Mean Cell Haemoglobin Concentration Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Carbon Dioxide Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gamma-Glutamyltransferase Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood Urea Nitrogen/Creatinine Ratio Decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Haematocrit Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood Cholesterol Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Haematocrit Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Red Cell Distribution Width Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Oropharngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The absence of a treatment group receiving a SE- or GLA-alone adjuvanted vaccine formulation is a limitation to the study conclusion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ruvim Izikson, M.D.</name_or_title>
      <organization>Protein Sciences Corporation</organization>
      <phone>203-599-6064 ext 163</phone>
      <email>rizikson@proteinsciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

